Glucotrack Files Lokahi Financials: $8.1M H1 Loss, $53K Cash, Going Concern Doubt
GCTK sits 16% above its 52-week low of $0.25 on light trading volume (0.1× avg).
Summary
Glucotrack's 8-K/A reveals Lokahi's H1 2026 loss of $8.1M, cash of just $53K, going concern doubt, and a new litigation threat — the first detailed financial look at the merged entity.
Key Events · M&A and Partnerships · GCTK
-
Lokahi H1 2026 Loss of $8.1M
Lokahi Therapeutics reported a net loss of $8,098,087 for the six months ended June 30, 2026, up from $3,064,590 in H1 2025, driven by higher R&D and G&A expenses plus $2.16M in interest expense on 2026 promissory notes.
-
Cash Crisis: $53K Cash, $6.8M Working Capital Deficit
As of June 30, 2026, Lokahi held only $53,186 in cash and cash equivalents against $9.1M in current liabilities, producing a working capital deficit of $6,846,937. The auditor's report includes a going concern emphasis of matter.
-
Pro Forma Combined Loss of $19.7M for H1 2026
The unaudited pro forma combined statement of operations shows a net loss of $19,699,822 for H1 2026, including a $2.7M day-one loss on bridge financing and $25.4M in IPR&D and $13.5M in goodwill from the acquisition.
-
Alto Litigation Threat Over $10.9M Note
In August 2026, Alto Opportunity Master Fund contacted counsel asserting the Company may bear responsibility for a $10.9M senior secured convertible note owed by APUS, and indicated intent to pursue litigation against the Company and others.
Analysis · GCTK · Industrial Applications And Services
This 8-K/A offers the first detailed look at Lokahi Therapeutics' standalone financials and the combined pro forma picture following the July 14 reverse merger. The numbers are stark: Lokahi lost $8.1M in H1 2026, holds just $53,186 in cash against $9.1M in current liabilities, and its auditor flags substantial doubt about its ability to continue as a going concern. The pro forma combined balance sheet shows $25.4M in IPR&D and $13.5M in goodwill from the acquisition, while the combined entity's pro forma net loss for H1 2026 reaches $19.7M. A new litigation threat from Alto Opportunity Master Fund over a $10.9M APUS note adds further risk. For a company with a market cap under $3M, these disclosures materially sharpen the survival picture.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCTK was trading at $0.29 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.25 to $14.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.